Study claims Covaxin has ability to neutralise new UK Covid strain
Reacting to the study s claims, ICMR tweeted Covaxin has equivalent immunogenicity against the UK-variant and circulating strains of SARS-COV-2 in India.
advertisement
Covaxin is being developed and manufactured by Bharat Biotech in collaboration with ICMR. (Representational image)
Covaxin, the Covid-19 vaccine candidate developed by Bharat Biotech, has the ability to neutralise the new UK variant of the virus causing Covid-19, according to a preprint review by bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences.
The archives operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution in New York.
Hyd-made Covaxin has ability to neutralize UK strain of COVID-19: Report
By PTI| Posted by Minhaj Adnan | Published: 27th January 2021 4:16 pm IST
Hyderabad: Covaxin, developed by Bharat Biotech, has the ability to neutralize the UK variant of the coronavirus, according to a preprint review by bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences.
The archiveis operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institutionin New York.
Bharat Biotech performed the plaque reduction neutralisation test (PRNT50) using sera collected from the 26 recipients of Covaxin and tested them against the UK variant and heterologous strain, the report said.
Covaxin jab effective against UK variant of coronavirus, claims study Covaxin - vaccine developed by Hyderabad-based Bharat Biotech - is effective against UK variants of COVID-19, according to a study on 26 participants, shared by the company on Wednesday. COVAXIN vaccine by Bharath Biotech.
Hyderabad: Covaxin, developed by Bharat Biotech, has the ability to neutralise the UK variant of the coronavirus , according to a preprint review by bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences.
The archive is operated by Cold Spring Harbor Laboratory, not-for-profit research and educational institution in New York.
Bharat Biotech performed the plaque reduction neutralisation test (PRNT50) using sera collected from the 26 recipients of Covaxin and tested them against the UK variant and heterologous strain, the report said.
13k volunteers administered 2nd dose of Covaxin in phase-3 trials: Bharat Biotech
India
Updated: Friday, January 22, 2021, 16:05 [IST]
Hyderabad, Jan 22: Bharat Biotech has successfully administered second dose of its COVID-19 vaccine Covaxin to 13,000 volunteers as part of its ongoing phase-3 clinical trials of the jab, Suchitra Ella joint managing director of Bharat Biotech said on Friday.
She said in a tweet, 13,000 volunteers have been successfully administered the 2nd dose in the phase-3 clinical trials of Covaxin. My heartfelt thanks to all of them for their pro-vaccine public health voluntarism. The city-based vaccine maker has successfully completed enrollment of25,800 volunteers for the Phase-3 trials of Covaxin, Ella had earlier said.
13,000 volunteers administered 2nd dose of Covaxin in phase-3 trials: Bharat Biotech
SECTIONS
Last Updated: Jan 22, 2021, 04:56 PM IST
Share
Synopsis
Covaxin is India s totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.
New York Times
The city-based vaccine maker has successfully completed enrollment of25,800 volunteers for the Phase-3 trials of Covaxin
Hyderabad: Bharat Biotech has successfully administered second dose of its COVID-19 vaccine Covaxin to 13,000 volunteers as part of its ongoing phase-3 clinical trials of the jab, Suchitra Ella joint managing director of Bharat Biotech said on Friday.
She said in a tweet, 13,000 volunteers have been successfully administered the 2nd dose in the phase-3 clinical trials of Covaxin. My heartfelt thanks to all of them for their pro-vaccine public health voluntarism.